

The Immunological Basis for Immunization Series

Module 10: *Varicella-zoster* virus

Immunization, Vaccines and Biologicals



**World Health
Organization**

The Immunological Basis for Immunization Series

Module 10: *Varicella-zoster virus*

Immunization, Vaccines and Biologicals



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The immunological basis for immunization series : Module 10: Varicella-zoster virus.

(Immunological basis for immunization series ; module 10)

1. Herpesvirus 3, Human - immunology. 2. Chickenpox vaccine - therapeutic use. 3. Chickenpox - immunology.
4. Herpes zoster vaccine - therapeutic use. 5. Herpes zoster - immunology. I. World Health Organization. II. Series.

ISBN 978 92 4 159677 0

(NLM classification: QW 165.5.H3)

© World Health Organization 2008

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This module was produced for Immunization, Vaccines and Biologicals, WHO, by:

Anne A. Gershon, MD, Department of Pediatrics, Columbia University, 650 West 168th St, BB427, New York, NY 10032, e-mail: aag1@columbia.edu

Grant support: AI 01703, AI 27187, AI 24021

Dr Gershon consults and lectures on varicella vaccine for Merck & Co., Inc. and GlaxoSmithKline (GSK).

Printed in May 2008

**Copies of this publications as well additional materials
on immunization, vaccines and biological may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland
• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2008

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

<i>Abbreviations and acronyms</i>	<i>v</i>
<i>Preface</i>	<i>vii</i>
1. Varicella-zoster virus (VZV) and its diseases	1
2. Live attenuated varicella vaccine	3
3. Immunity to varicella	4
4. Techniques useful to measure antibodies and cell-mediated immune (CMI) to varicella-zoster virus (VZV)	5
5. Protective antibody responses	7
6. Vaccine efficacy and effectiveness	8
7. Persistence of antibodies after vaccination	11
8. Safety	15
References	16

Abbreviations and acronyms

ACV	acyclovir
CA	California (USA)
CDC	Centers for Disease Control (USA)
CMI	cell-mediated immune
CSF	cerebrospinal fluid
DNA	deoxyribonucleic acid
ELISA	enzyme-linked immunosorbent assay
FAMA	fluorescent antibody to membrane antigen
GMT	geometric mean titre
gpELISA	glycoprotein ELISA (test)
GSK	GlaxoSmithKline
HELF	human embryonic lung fibroblasts
Ig	immunoglobulin
MA	Massachusetts (USA)
MMR	measles-mumps-rubella (vaccine)
MMRV	measles-mumps-rubella-varicella (vaccine)
NY	New York (USA)
PA	Pennsylvania (USA)
PCR	polymerase chain reaction
PFU	plaque forming unit
SI	International System of Units
TA	Texas (USA)
TN	Tennessee (USA)
VZIG	varicella-zoster immune globulin
VZV	varicella-zoster virus
VZVIP	Varicella Zoster Virus Identification Program (USA)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29362

